Who are Dimephosphon®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Boniva, Skelid, Aredia, Didronel, FOSAMAX PLUS D, Ibandronate IV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dimephosphon.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Dimephosphon® — Competitive Intelligence Brief

Dimephosphon® (Dimephosphon®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bisphosphonate. Area: Bone metabolism / Rheumatology.

phase 3 Bisphosphonate Farnesyl pyrophosphate synthase (indirect); osteoclast function Bone metabolism / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Dimephosphon® (Dimephosphon®) — Tatchempharmpreparaty, JSC. Dimephosphon is a bisphosphonate that inhibits bone resorption by suppressing osteoclast activity and promoting osteoclast apoptosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dimephosphon® TARGET	Dimephosphon®	Tatchempharmpreparaty, JSC	phase 3	Bisphosphonate	Farnesyl pyrophosphate synthase (indirect); osteoclast function
Boniva	IBANDRONIC ACID	Hoffmann La Roche	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase	2003-01-01
Skelid	TILUDRONIC ACID		marketed	Bisphosphonate	72 kDa type IV collagenase	1997-01-01
Aredia	PAMIDRONIC ACID		marketed	Bisphosphonate	Farnesyl pyrophosphate synthase	1991-01-01
Didronel	ETIDRONIC ACID	Procter And Gamble	marketed	Bisphosphonate		1977-01-01
FOSAMAX PLUS D	FOSAMAX PLUS D	Organon and Co	marketed	Bisphosphonate + vitamin D3 combination	Osteoclast proton pump (alendronate); vitamin D receptor (cholecalciferol)
Ibandronate IV	Ibandronate IV	National Taiwan University Hospital	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase; hydroxyapatite in bone

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bisphosphonate class)

· 2 drugs in this class
Amgen · 2 drugs in this class
National Taiwan University Hospital · 2 drugs in this class
Sanofi · 2 drugs in this class
Ludwig-Maximilians - University of Munich · 2 drugs in this class
Chinese University of Hong Kong · 1 drug in this class
Chinese Society of Lung Cancer · 1 drug in this class
Aarhus University Hospital · 1 drug in this class
Eisai Inc. · 1 drug in this class
Daiichi Sankyo Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dimephosphon® — Competitive Intelligence Brief. https://druglandscape.com/ci/dimephosphon. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab